BioNTech CEO confident Covid vaccine works against ‘double mutant’ strain identified in India – CNBC
|Early Friday morning in Asia, CNBC quotes BioNTech CEO Ugur Sahin while stating, “He is ‘confident’ the company’s Covid-19 vaccine with US partner Pfizer is effective against a coronavirus variant first identified in India.”
The news further said, “The strain, known as B.1.617, contains two key mutations that have been found separately in other coronavirus variants. The variant, also referred to as the ‘double mutant’ was first spotted in India where it’s thought by some to be behind a recent surge in new Covid-19 cases there.”
It should, however, be noted that Sahin said the company won’t know for sure until it has more data, per the news.
Market reaction
Following the recent challenges to the market sentiment, as well as lack of confirmation in the BioNTech story, global markets paid a little heed to the news as S&P 500 Futures seesaw around 4,200 by the press despite Wall Street’s upbeat performance.
Also read: AstraZeneca’s struggle, China’s fresh restrictions on big techs may weigh on sentiment
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.